PetMed Express (NASDAQ: PETS) and Delcath Systems (NASDAQ:DCTH) are both small-cap retail/wholesale companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends and profitabiliy.

Analyst Ratings

This is a summary of current ratings and price targets for PetMed Express and Delcath Systems, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PetMed Express 1 0 1 0 2.00
Delcath Systems 0 0 0 0 N/A

PetMed Express presently has a consensus target price of $13.00, suggesting a potential downside of 66.03%. Given PetMed Express’ higher possible upside, equities research analysts clearly believe PetMed Express is more favorable than Delcath Systems.

Earnings and Valuation

This table compares PetMed Express and Delcath Systems’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
PetMed Express $249.18 million 3.12 $38.85 million $1.17 32.71
Delcath Systems $2.37 million 2.50 -$16.90 million N/A N/A

PetMed Express has higher revenue and earnings than Delcath Systems.

Profitability

This table compares PetMed Express and Delcath Systems’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
PetMed Express 9.56% 26.69% 23.42%
Delcath Systems -1,161.00% -1,403.27% -76.07%

Volatility & Risk

PetMed Express has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Comparatively, Delcath Systems has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500.

Insider and Institutional Ownership

78.3% of PetMed Express shares are owned by institutional investors. Comparatively, 1.5% of Delcath Systems shares are owned by institutional investors. 4.7% of PetMed Express shares are owned by company insiders. Comparatively, 4.5% of Delcath Systems shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Dividends

PetMed Express pays an annual dividend of $0.80 per share and has a dividend yield of 2.1%. Delcath Systems does not pay a dividend. PetMed Express pays out 68.4% of its earnings in the form of a dividend.

Summary

PetMed Express beats Delcath Systems on 11 of the 13 factors compared between the two stocks.

About PetMed Express

PetMed Express, Inc. (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies. Its products include brands of medication, such as Frontline Plus, K9 Advantix II, Advantage II, Heartgard Plus, Sentinel, Revolution and Rimadyl. It also offers additional pet supplies for sale on its Website, which are drop shipped to its customers by third parties. These pet supplies include food, beds, crates, stairs, strollers and other pet supplies. Its products included Non-Prescription Medications (Over the Counter (OTC)) and supplies, and Prescription Medications (Rx). Its customers are located in California, Florida, Texas, New York, Virginia and Georgia, among others.

About Delcath Systems

Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company’s system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company’s focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.

Receive News & Ratings for PetMed Express Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express Inc. and related companies with MarketBeat.com's FREE daily email newsletter.